Abstract:PURPOSE:MicroRNAs (miRNAs) are short non-coding RNA molecules, which post-transcriptionally regulate genes expression and play crucial roles in diverse biological processes. Recent studies have shown that dysregulation of miRNAs might modulate the resistance of cancer cells to anti-cancer drugs, yet the modulation mechanism is not fully understood. We aimed to investigate the possible role of miRNAs in the development of multidrug resistance (MDR) in human gastric and lung cancer cell lines.METHODS:miRNA Quantitative real-time PCR was used to detect the different miRNA expression levels between drug resistant and parental cancer cells. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was used to test the drug-resistant phenotype changes in cancer cells via over or downregulation of miRNAs. Dual-luciferase activity assay was used to verify the target genes of miRNAs. Western blot analysis and apoptosis assay were used to elucidate the mechanism of miRNAs on modulating drug resistance in cancer cells.RESULTS:miR-200bc/429 cluster was downregulated, while BCL2 and XIAP were upregulated in both MDR SGC7901/VCR (vincristine) and A549/CDDP (cisplatin) cells, compared with the parental SGC7901 and A549 cells, respectively. Overexpression of miR-200bc/429 cluster sensitized SGC7901/VCR and A549/CDDP cells to anti-cancer drugs, respectively. Both BCL2 and XIAP 3'-UTR reporters constructed in MDR cells suggested that BCL2 and XIAP were the common target genes of the miR-200bc/429 cluster. Enforced miR-200bc/429 cluster expression reduced BCL2 and XIAP protein level and sensitized both MDR cells to VCR-induced and CDDP-induced apoptosis, respectively.CONCLUSIONS:Our findings first suggest that miR-200bc/429 cluster could play a role in the development of MDR in both gastric and lung cancer cell lines, at least in part by modulation of apoptosis via targeting BCL2 and XIAP.

Mir-1915 Inhibits Bcl-2 to Modulate Multidrug Resistance by Increasing Drug-Sensitivity in Human Colorectal Carcinoma Cells.

Mir-181b Modulates Multidrug Resistance By Targeting Bcl2 In Human Cancer Cell Lines

Mir-15b and Mir-16 Modulate Multidrug Resistance by Targeting Bcl2 in Human Gastric Cancer Cells

Mir-200Bc/429 Cluster Modulates Multidrug Resistance of Human Cancer Cell Lines by Targeting BCL2 and XIAP.

Mir-139-5p Inhibits the Epithelial-Mesenchymal Transition and Enhances the Chemotherapeutic Sensitivity of Colorectal Cancer Cells by Downregulating BCL2

Mir-222 Modulates Multidrug Resistance in Human Colorectal Carcinoma by Down-Regulating Adam-17

Mir-297 Modulates Multidrug Resistance in Human Colorectal Carcinoma by Down-Regulating Mrp-2

H19-Derived Mir-675 Functions As An Oncogenic Microrna In Human Colorectal Cancers Through Targeting The Rb Tumor Suppressor

Data from Mir200c Attenuates P-gp–Mediated MDR and Metastasis by Targeting JNK2/c-Jun Signaling Pathway in Colorectal Cancer

miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2

Mir-191 Promotes Tumorigenesis of Human Colorectal Cancer Through Targeting C/EBPβ.

Mir-503 Regulates the Resistance of Non-Small Cell Lung Cancer Cells to Cisplatin by Targeting Bcl-2.

Mir-503-5p Confers Drug Resistance by Targeting PUMA in Colorectal Carcinoma

Role Of Microrna Mir-27a And Mir-451 In The Regulation Of Mdr1/P-Glycoprotein Expression In Human Cancer Cells

Changes in the Expression of Mir-381 and Mir-495 Are Inversely Associated with the Expression of the MDR1 Gene and Development of Multi-Drug Resistance

Mir-135A/b Modulate Cisplatin Resistance of Human Lung Cancer Cell Line by Targeting MCL1

MiR-139-5p Reverses CD44+/CD133+-associated Multidrug Resistance by Downregulating NOTCH1 in Colorectal Carcinoma Cells

Mir-193B Directly Targets STMN1 and Inhibits the Malignant Phenotype in Colorectal Cancer.

Mir-122 Targets X-Linked Inhibitor of Apoptosis Protein to Sensitize Oxaliplatin-Resistant Colorectal Cancer Cells to Oxaliplatin-Mediated Cytotoxicity

miR-199b-3p contributes to acquired resistance to cetuximab in colorectal cancer by targeting CRIM1 via Wnt/β-catenin signaling

Mir-204-5p Inhibits Proliferation and Invasion and Enhances Chemotherapeutic Sensitivity of Colorectal Cancer Cells by Downregulating RAB22A.